Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial

Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial

Abstract Objectives This study aimed to evaluate the efficacy, adverse events, patient compliance, and cost of dual therapy with Ilaprazole-amoxicillin (IA) at high dose versus Ilaprazole-amoxicillin-furazolidone-bismuth (IAFB) quadruple therapy for the Helicobacter pylori (H.pylori) infection among...

Full description

Bibliographic Details
Main Authors: Xiao-Dong Zhang, Da-Ya Zhang, Run-Xiang Chen, Shi-Ju Chen, Chen Chen, Fan Zeng, Shi-Mei Huang, Da Li, Fei-Hu Bai
Format: Article
Language:English
Published: BMC 2023-07-01
Series:BMC Gastroenterology
Subjects:
Helicobacter pylori
Dual therapy
Quadruple therapy
Ilaprazole
Eradication rate
Noninferiority
Online Access:https://doi.org/10.1186/s12876-023-02890-5

Internet

https://doi.org/10.1186/s12876-023-02890-5

Similar Items